

Acknowledgements

We thank the medical and nursing staff working on the Fukuoka Blood and Marrow Transplantation Group for providing patients samples and information. We also are grateful to Chugai Pharmaceutical Co. (Tokyo, Japan) for information about rituximab. This work was supported in part by a Grant-in-Aid from Daiwa Securities Health Foundation, Tokyo, Japan to TM.

References

- 1 Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D *et al*. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. *N Engl J Med* 1995; **333**: 1540–1545.
- 2 Pettengell R, Radford JA, Morgenstern GR, Scarffe JH, Harris M, Woll PJ *et al*. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. *J Clin Oncol* 1996; **14**: 586–592.
- 3 Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C *et al*. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. *N Engl J Med* 2004; **350**: 1287–1295.
- 4 Mangel J, Leitch HA, Connors JM, Buckstein R, Imrie K, Spaner D *et al*. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. *Ann Oncol* 2004; **15**: 283–290.
- 5 Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF *et al*. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. *J Clin Oncol* 1999; **17**: 268–276.
- 6 Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P *et al*. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. *J Clin Oncol* 2001; **19**: 389–397.
- 7 Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R *et al*. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med* 2002; **346**: 235–242.
- 8 Flinn IW, Lazarus HM. Monoclonal antibodies and autologous stem cell transplantation for lymphoma. *Bone Marrow Transplant* 2001; **27**: 565–569.
- 9 Nademanee A, Forman SJ. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B. *Semin Hematol* 2006; **43**: 240–250.
- 10 Buckstein R, Imrie K, Spaner D, Potichnyj A, Robinson JB, Nanji S *et al*. Stem cell function and engraftment is not affected by 'in vivo purging' with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. *Semin Oncol* 1999; **26**: 115–122.
- 11 Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L *et al*. Successful *in vivo* purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. *Blood* 2000; **96**: 864–869.
- 12 Benekli M, Hahn T, Shafi F, Qureshi A, Alam AR, Czuczman MS *et al*. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. *Bone Marrow Transplant* 2003; **32**: 139–143.
- 13 Hoerr AL, Gao F, Hidalgo J, Tiwari D, Blum KA, Mathews V *et al*. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. *J Clin Oncol* 2004; **22**: 4561–4566.
- 14 Papayannopoulou T. Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. *Blood* 2004; **103**: 1580–1585.
- 15 Imamura R, Miyamoto T, Yoshimoto G, Kamezaki K, Ishikawa F, Hengan H *et al*. Mobilization of human lymphoid progenitors after treatment with granulocyte colony-stimulating factor. *J Immunol* 2005; **175**: 2647–2654.
- 16 The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. *N Engl J Med* 1993; **329**: 987–994.
- 17 Teshima T, Harada M, Takamatsu Y, Makino K, Inaba S, Akashi K *et al*. Granulocyte colony-stimulating factor (G-CSF)-induced mobilization of circulating haemopoietic stem cells. *Br J Haematol* 1993; **84**: 570–573.
- 18 Makino S, Harada M, Akashi K, Taniguchi S, Shibuya T, Inaba S *et al*. A simplified method for cryopreservation of peripheral blood stem cells at –80 degrees C without rate-controlled freezing. *Bone Marrow Transplant* 1991; **8**: 239–244.
- 19 Chow KU, Nowak D, Kim SZ, Schneider B, Komor M, Boehrer S *et al*. *In vivo* drug-response in patients with leukemic non-Hodgkin's lymphomas is associated with *in vitro* chemosensitivity and gene expression profiling. *Pharmacol Res* 2006; **53**: 49–61.
- 20 van Heeckeren WJ, Vollweiler J, Fu P, Cooper BW, Meyerson H, Lazarus HM *et al*. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: *in vivo* purging with rituximab versus *ex vivo* purging with CliniMACS CD34 cell enrichment device. *Br J Haematol* 2006; **132**: 42–55.
- 21 To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. *Blood* 1997; **89**: 2233–2258.
- 22 Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. *N Engl J Med* 2003; **348**: 2691–2694.
- 23 Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. *Br J Haematol* 2003; **121**: 913–918.
- 24 Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T *et al*. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. *Blood* 2005; **106**: 795–802.
- 25 Lemieux B, Tartas S, Traulle C, Espinouse D, Thieblemont C, Bouafia F *et al*. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. *Bone Marrow Transplant* 2004; **33**: 921–923.
- 26 Cairoli R, Grillo G, Tedeschi A, D'Avanzo G, Marengo P, Morra E. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. *Haematologica* 2004; **89**: 361–363.